Results 21 to 30 of about 696 (142)

Modulation of Mast Cells by Epicutaneous Immunotherapy (EPIT) to Cashew Allergy [PDF]

Journal of Allergy and Clinical Immunology, 2021
Pierre‐Louis Hervé, Audrey Perrin, Nathalie Oreal, Camille Plaquet, Laetitia Gaulme, Noémie Assoun, Katie Matthews, Jean‐Louis Labernardière, Hugh A. Sampson   +8 more
openalex   +2 more sources

Epicutaneous Immunotherapy (EPIT) for Peanut Allergy in Young Children [PDF]

Journal of Allergy and Clinical Immunology, 2019
David M. Fleischer, Terri F. Brown‐Whitehorn, Stacie M. Jones, Edwin Kim, Kari C. Nadeau, Julie Wang, Robert A. Wood, Anna Nowak‐Węgrzyn, Arthur Jaffrelot, Todd David Green, A. Wesley Burks   +10 more
openalex   +2 more sources

Efficacy and Safety of Epicutaneous Immunotherapy (EPIT) for Peanut Allergy in Subjects Aged 1-3 Years With and Without Atopic Dermatitis in the EPITOPE Study [PDF]

Journal of Allergy and Clinical Immunology, 2023
Amy M. Scurlock, Katharine J. Bee, Hugh A. Sampson, Jonas Meney, Henry T. Bahnson, A. Wesley Burks   +5 more
openalex   +2 more sources

Improvements in Quality of Life in Children Following Epicutaneous Immunotherapy (EPIT) for Peanut Allergy in PEPITES and PEOPLE Studies [PDF]

Pediatrics, 2021
Mechelle A. Miller, Karla L. Davis
openalex   +2 more sources

Epicutaneous Immunotherapy (EPIT) for House Dust Mite (HDM) Allergy using VIASKIN® Technology: a Preclinical Study [PDF]

Journal of Allergy and Clinical Immunology, 2009
Lucie Mondoulet, Pierre‐Henri Benhamou, Mélanie Ligouis, S. Chariglione, Christophe Dupont   +4 more
openalex   +2 more sources

Efficacy and Safety of Epicutaneous Immunotherapy (EPIT) for Peanut Allergy in Subjects Aged 1-3 Years With and Without Concomitant Food Allergies in the EPITOPE Study [PDF]

Journal of Allergy and Clinical Immunology, 2023
David E. Fleischer, Todd D. Green, Hugh A. Sampson, Jonas Meney, Henry T. Bahnson, A. Wesley Burks   +5 more
openalex   +2 more sources

Recent advances in food allergen immunotherapy. [PDF]

Clin Exp Pediatr
Food allergies can pose significant risks and profoundly impact the quality of life of children and their families, making them a major public health concern. Allergen avoidance has been the traditional mainstay of treatment; however, recent research has
Jeon YH, Kim EH.
europepmc   +3 more sources

Improvements in eliciting dose across baseline sensitivities following 12 months of epicutaneous immunotherapy (EPIT) in peanut-allergic children aged 4 to 11 years

The Journal of Allergy and Clinical Immunology: In Practice, 2020
Matthew Greenhawt, Edwin Kim, Dianne E. Campbell, Todd D. Green, Romain Lambert, David M. Fleischer   +5 more
openalex   +3 more sources

Results of the REALISE (Real-life Use and Safety of EPIT) Study: A Multicenter Blinded Randomized Controlled Trial Investigating the Safety of Epicutaneous Immunotherapy for Peanut Allergy in Peanut-Allergic Children [PDF]

Journal of Allergy and Clinical Immunology, 2020
Jacqueline A. Pongracic, Rémi Gagnon, Gordon L. Sussman, Dareen Siri, Roxanne C. Oriel, Terri Brown‐Whitehorn, Todd D. Green, Dianne E. Campbell, Robin Mukherjee, Philippe Bégin   +9 more
openalex   +3 more sources

Application of PLGA-PEG-PLGA Nanoparticles to Percutaneous Immunotherapy for Food Allergy [PDF]

Molecules
Compared with oral or injection administration, percutaneous immunotherapy presents a promising treatment modality for food allergies, providing low invasiveness and safety. This study investigated the efficacy of percutaneous immunotherapy using hen egg
Ryuse Sakurai, Hanae Iwata, Masaki Gotoh, Hiroyuki Ogino, Issei Takeuchi, Kimiko Makino, Fumio Itoh, Akiyoshi Saitoh   +7 more
doaj   +2 more sources